<DOC>
	<DOC>NCT01824992</DOC>
	<brief_summary>to assess the efficacy and safety of recombinant human interferon α-2b gel (Yallaferon®) for the treatment of patients with cervical high-risk HPV infections; to analyze the HPV type infections and clinical negative conversion. 285 patients with positive high risk HPV infection were randomized into interferon gel group and control group at ratio of 2:1 (203 patients in treatment group and 82 patients in control group). The patients in treatment group received 1g recombinant human α-2b interferon gel every other day for consecutive 3 courses of treatment, whereas no treatment was conducted in control group.</brief_summary>
	<brief_title>Recombinant Human Interferon a-2b Gel for HPV Gynecological Infections</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<criteria>1. Age 30 to 65 years of age the sex life of female patients; 2. , liquidbased cytology (TCT) check no intraepithelial lesions and malignant cells; 3. , HPV DNA typing test for highrisk HPV positive (including a single highrisk type positive, and more highrisk type of positive and highand lowrisk hybrid positive). 15 kinds of highrisk types, including HPV16, 18,31,33,35,39,45,51,52,53,56,58,59,66,68 (1) cervical intraepithelial neoplasia (CIN); (2), combined with a severe fungal, trichomonas vaginitis; (3), severe primary diseases associated with cardiovascular, liver, kidney and hematopoietic system; (4), allergies or allergy to the drug known ingredients. (5), within 30 days to accept other clinical trials of drugs or are participating in clinical trials; (6), pregnant and lactating women and to be pregnant women; (7), the researchers do not consider it appropriate clinical trials.</criteria>
	<gender>Female</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2013</verification_date>
</DOC>